Skip to main content
. 2011 Nov 27;61(2):249–254. doi: 10.1007/s00262-011-1153-9

Table 1.

HLA class I abnormalities in human tumors

Highly variable frequency in many tumors
Total HLA class I antigen loss (9–52%)
HLA class I downregulation (3–20%)
Selective loss or downregulation of HLA class I allospecificities (15–50%)
Association with disease progression
Tissue and/or tumor subtype specificity
Differentiation/cell cycle dependence